Résumé
Perioperative inflammation assessment can be used to screen and stratify the perioperative status of the cancer patient. Biomarkers such as the neutrophil-to-lymphocyte ratio help clinicians and researchers develop and apply new screening and monitoring strategies. To control the perioperative inflammatory reaction, and to promote early resolution, pharmacological interventions such as NSAIDs are proposed as promising. One of their applications is the prevention of the early peak of recurrence, seen in the first few years after surgery. Additionally, to progress toward the development of new options a combined role of database analyses and incorporation of biomarkers is proposed.